Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

11/19/24 8:00:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ITCI alert in real time by email

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Evercore 7th Annual HealthCONx Conference

Tuesday, December 3, 2024 at 10:50 a.m. ET in Miami, FL

Citi 2024 Global Healthcare Conference

Wednesday, December 4, 2024 at 3:15 p.m. ET in Miami, FL

Piper Sandler 36th Annual Healthcare Conference

Thursday, December 5, 2024 at 11:30 a.m. ET in New York, NY

A live and achieved webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic

[email protected]

646-930-4406

Get the next $ITCI alert in real time by email

Recent Analyst Ratings for

$ITCI

Date	Price Target	Rating	Analyst
2/24/2025	$140.00 → $132.00	Outperform → Neutral	Mizuho
1/31/2025	$119.00 → $132.00	Buy → Hold	Canaccord Genuity
9/6/2024	$68.00 → $92.00	Neutral → Overweight	Piper Sandler
1/3/2024	$83.00	Outperform	Robert W. Baird
12/11/2023	$75.00	Outperform	TD Cowen
4/20/2023	$80.00	Overweight	Morgan Stanley
8/22/2022	$64.00 → $49.00	Buy → Neutral	Goldman
7/7/2022	$74.00	Buy	Mizuho

More analyst ratings

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for
$ITCI

$ITCI
SEC Filings

SEC Form 15-12G filed by Intra-Cellular Therapies Inc.

SEC Form EFFECT filed by Intra-Cellular Therapies Inc.

SEC Form POSASR filed by Intra-Cellular Therapies Inc.

$ITCI
Press Releases

Fastest customizable press release news feed in the world

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

$ITCI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Intra-Cellular Therapies downgraded by Mizuho with a new price target

Intra-Cellular Therapies downgraded by Canaccord Genuity with a new price target

Intra-Cellular Therapies upgraded by Piper Sandler with a new price target

$ITCI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)

Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)

President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $ITCI

$ITCI SEC Filings

SEC Form 15-12G filed by Intra-Cellular Therapies Inc.

SEC Form EFFECT filed by Intra-Cellular Therapies Inc.

SEC Form POSASR filed by Intra-Cellular Therapies Inc.

$ITCI Press Releases

Fastest customizable press release news feed in the world

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

$ITCI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Intra-Cellular Therapies downgraded by Mizuho with a new price target

Intra-Cellular Therapies downgraded by Canaccord Genuity with a new price target

Intra-Cellular Therapies upgraded by Piper Sandler with a new price target

$ITCI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)

Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)

President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)

Recent Analyst Ratings for
$ITCI

$ITCI
SEC Filings

$ITCI
Press Releases

$ITCI
Analyst Ratings

$ITCI
Insider Trading